What's New in Vaccine Immunology Webinar

October 26, 2023

What's New in Vaccine Immunology? Getting inoculated with new knowledge. Vaccines are foundational in public health policy because they save millions of lives by preventing/mitigating many infectious diseases caused by bacteria and viruses. With the availability of new technologies and adjuvants, vaccine immunology is rapidly evolving. Clinical immunologists are often called upon to educate colleagues and patients about vaccines including management of adverse reactions to vaccines.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

After completing this webinar, participants should be able to: 
1.      Classify adverse reactions to vaccines as IgE mediated, non-IgE mediated, vasovagal or immunization stress-related response. 
2.      Review up to date evidence of inflammatory hypersensitivity reactions to mRNA COVID-19 vaccinations and smallpox vaccines presenting as myocarditis and pericarditis. 
3.      Determine optimal timing of vaccinations in patients treated with biologics and immunosuppressants. 
4.      Update and gain knowledge of vaccine immunology in 2023 – where it’s been and where it is going. 
 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 CBRN
Course opens: 
10/27/2023
Course expires: 
12/31/2023
Event starts: 
10/26/2023 - 7:00pm CDT
Event ends: 
10/26/2023 - 8:00pm CDT
Add to calendar: 
Rating: 
0

Karla Adams, MD | Is an Associate Professor of Pediatrics and a practicing Allergist in San Antonio, Texas. She obtained her medical degree from the Uniformed Services University then completed a Pediatrics residency and Allergy and Immunology Fellowship at the San Antonio Uniformed Services Health Education Consortium in San Antonio, TX. She is currently the Program Director for the Allergy and Immunology Fellowship at Wilford Hall Ambulatory Surgical Center, San Antonio, TX

Sara Anvari, MD, MSc | As the Director of Clinical Trials for the TCH Food Allergy Program, Sara Anvari, MD, MSc has been an advocate for food allergic patients and has helped develop and bring the latest food allergy clinical trials to Texas Children's Hospital.  In addition to her strong interest in preventing and treating all forms of allergic and immunological conditions, Dr. Anvari has established subspecialty clinics focused on treating patients with food protein-induced enterocolitis syndrome (FPIES), COVID vaccine hypersensitivity reactions, and penicillin allergy delableing. She is committed to improving the quality of life for infants, children and adolescents with allergic and immunologic disorders. Dr. Anvari currently leads clinical and basic science research projects evaluating food, drug, and vaccine allergies. She has dedicated her career, thus far, to understand and investigate the underlying immune mechanisms driving these conditions. 

Joel Brooks, DO, MPH | Joel Brooks is an Assistant Professor of Pediatrics at the Columbia University Vagelos College of Physicians and Surgeons where he serves as the Associate Program Director of their Allergy and Immunology Fellowship Program. He also serves on several committees for the American College of Allergy, Asthma, and Immunology and American Academy of Allergy, Asthma, and Immunology, including their Vaccine Committee.

Renata J. M. Engler, MD, FAAAI, FACAAI, FACP | is a Professor in the Department of Medicine & Pediatrics at the Uniformed Services University of the Health Sciences and is a retired Army Colonel with 38 years of service. She was a former training program director and was a past member of the American Board of Allergy and Immunology. Dr.  Engler received her MD at Georgetown University and holds board certifications in Internal Medicine, Allergy-Immunology, and a conjoint board certification in Diagnostic Laboratory Immunology.  Dr. Engler’s expertise is in cardiovascular immunology, allergy-immunology-diagnostic laboratory immunology as related to systemic inflammation, immune modulation, and vaccine responses. As a senior physician educator, researcher and clinician with 20 years focused on research related to vaccine safety/efficacy and biodiversity of adverse events related to vaccines, Dr. Engler has in depth experience with systemic inflammation as a risk factor and major drivers of cardiovascular disease morbidity and mortality as well as in the context of adverse events like myocarditis after vaccines. 

All identified relevant financial relationships with ineligible companies have been mitigated.

Karla Adams, MD | Moderator
Sara Anvari, MD | Panelist
Joel Brooks, DO | Panelist
Renata J.M. Engler, MD | Panelist
Mary Hudelson, MD | Planner
Joel Klein, MD | Planner
Joram Seggev, MD | Reviewer

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 CBRN
Please login or create an account to take this course.